Deming David H bought 6,800 shares of Phio Pharmaceuticals Corp. at $0.84 for $5.71k on Nov 10, 2026

Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Director
DIR
Filed Nov 12, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$5,708.60Shares × reported price
Shares traded
6,800Common Stock, $.0001 par value
Price per share
$0.84Reported price. Read footnotes for ranges.
% of reported position traded
17.99%This security and ownership context
Holdings after
44,600Direct
Trade date
Nov 10, 2026Buy
Filed
Nov 12, 2026, 9:52 AM ET2-day reporting delay
Accession
0001683168-26-008544Code P · Transaction 398315
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 37,800 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 11, 2026Buy5,200$0.84$4,357.60Trade 398316
2 transaction rows in this filing. Joint filers share the same rows.

PHIO price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
PHIO · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 19, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +20%1w ago +6.2%1d ago +6.2%
Returns since7d30d90d180d1y

Footnotes in full

F1: The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.8079 to $0.8600 per share on November 10, 2026. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: Includes shares of common stock underlying unvested restricted stock units. F3: The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.8269 to $0.8600 per share on November 11, 2026. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.